Form 4: Protara CFO Sells Shares for Tax Obligations

Protara Therapeutics' CFO, Patrick Fabbio, disposed of 3,063 common shares at $5.6 each to cover tax liabilities from a restricted stock unit award.

Summary

• Patrick Fabbio, Chief Financial Officer of Protara Therapeutics, Inc. (TARA), reported a transaction on January 20, 2026.
• Fabbio disposed of 3,063 shares of Protara Therapeutics Common Stock.
• The shares were disposed of at a price of $5.6 per share.
• This disposition was to satisfy income tax obligations related to the vesting of a Restricted Stock Unit (RSU) Award granted on January 19, 2024.
• Following this transaction, Fabbio beneficially owns 67,376 shares of Common Stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common occurrence for executives receiving equity compensation. It does not indicate positive or negative sentiment towards the company's prospects.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it pertains solely to an insider transaction.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect broader industry trends or specific company performance.

Related Party Transactions

• The transaction involves the disposition of shares by the Chief Financial Officer to the issuer to satisfy income tax obligations, which is a standard related-party dealing for equity compensation.

Stakeholder Impact

• Shareholders will observe a minor reduction in the CFO's direct shareholding, but this is due to a non-discretionary tax-related event and is unlikely to impact investor confidence significantly.

Key Dates

Recommendation

This Form 4 reports a non-discretionary disposition of shares by the CFO to cover tax obligations upon the vesting of a Restricted Stock Unit award. Such transactions are common and do not typically signal a change in management's confidence or the company's fundamentals. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Protara Therapeutics, TARA, Patrick Fabbio, CFO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Unit, RSU